Abstract A dual-action ligand targeting both integrin α V β 3 and vascular endothelial growth factor receptors (VEGFRs), was synthesized via conjugation of a cyclic peptidomimetic α V β 3 Arg-Gly-Asp (RGD) ligand with a decapentapeptide. The latter was obtained from a known